Publications Internationales

1. . N. Veziris, C. Bernard, L. Guglielmetti, D. Le Dû, D. Marigot-Outtandy, M. Jaspard, E. Caumes, I. Lerat, C. Rioux, Y. Yazdanpanah, A. Tiotiu, N. Lemaitre, F. Brossier, V. Jarlier, J. Robert, W. Sougakoff, A. Aubry. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance : lessons not to repeat past errors. European Respiratory Journal. 2017 Mar 22 ;49(3). pii : 1601719.
2. . T. Maitre, G. PetitJean, A. Chauffour, C. Bernard, N. El Helali, V. Jarlier, F. Reibel, P. Chavanet, A. Aubry, N. Veziris. Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis ? Journal of Antimicrobial Chemotherapy. 2017 2017 Aug 1 ;72(8):2326-2333
3. . E. Lecorche, S. Haenn, F. Mougari ; et al. Comparison of methods available for the identification of Mycobacterium chimaera. Clinical microbiology and infection Epub 2017 Aug 4
4. . Guglielmetti L. Bedaquiline for the treatment of multidrug-resistant tuberculosis : another missed opportunity ? Eur Respir J 2017 :49. (editorial)
5. . Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N, Ndjeka N, Setkina S, Shabangu A, Sikhondze W, et al. 2017. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. Int J Tuberc Lung Dis. 2017, 21, 167–174.
6. . Mougari F, Loiseau J, Veziris N, Bernard C, Bercot B, Sougakoff W, Jarlier V, Raskine L, Cambau E ; French National Reference Center for Mycobacteria. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother. 2017 Jun 1 ;72(6):1669-1677. Rapport d’activités CNR-MyRMA pour l’année 2017 Page 69 sur 100 -#. Appelgren A, Morquin D, Dufour S, Le Moing V, Reynes J, Lotthé A, Parer S, Corbeau C, Aubry A, Sougakoff W, Solassol J, Bonzon L, Dumont Y, Godreuil S. 2017. Investigation of a pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France. J Hosp Infect. 2017 Jun 29. pii : S0195- 6701(17)30377-8.
7. . Maitre T, Aubry A, Veziris N. Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 2017 Dec 14 ;377(24):2403-4.
8. . D’Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB. Team approach to manage difficult-to-treat TB cases : Experiences in Europe and beyond. Pulmonology. Epub 2017 Dec 8.
9. . Fournier A, Bernard C, Sougakoff W, Quelet S, Antoun F, Charlois-Ou C, Dormant I, Dufour MO, Hocine N, Jarlier V, Veziris N. Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission. Eur Respir J. 2017 Sep 11 ;50(3). pii : 1700891.
10. . Jaspard M, Elefant-Amoura E, Melonio I, De Montgolfier I, Veziris N, Caumes E. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. Emerg Infect Dis. 2017 Oct ;23(10).
11. . van Leth F, Günther G, Hoffmann H, Lange C ; European MDR-TB DatabaseCollaboration. Reply : Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. Am J Respir Crit Care Med. 2017 Dec 1 ;196(11):1489-1490.
12. . Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, Veziris N, Robert J, Yazdanpanah Y, Caumes E, Fréchet-Jachym M ; French MDR-TB Management Group. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017 Mar 22 ;49(3).
13. . Brossier F, Pham A, Bernard C, Aubry A, Jarlier V, Veziris N, Sougakoff W ; CNR-MyRMA. Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother. 2017 Jan 24 ;61(2). pii : e01299-16.
14. . Mougari F, Bouziane F, Crockett F, Nessar R, Chau F, Veziris N, Sapriel G, Raskine L, Cambau E. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother. January 2017 Volume 61 Issue 1 e00943-16.
15. . Guglielmetti L, Veziris N, Aubry A, Brossier F, Bernard C, Sougakoff W, Jarlier V, Robert J. Risk factors for extensively drug resistance in multidrug-resistant tuberculosis cases : a case-case study. Int J Tuberc Lung Dis, 2017, https://doi.org/10.5588/ijtld.17.0387
16. . Rueda D, Bernard C, Gondy L, Capton E, Boudjelloul R, Brossier F, Veziris N, Zimic M, Sougakoff W. Estimation of pyrazinamidase activity using a cell-free in vitro synthesis of PncA and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis. Int J Mycobacteriol, 2018, 7(1):16-25.
17. . Leyer C, Gregorowicz G, Mougari F, Raskine L, Cambau E, de Briel D. Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media., J Clin Microbiol, 2017, 55, 2045-2054.
18. . Delafont V, Samba-Louaka A, Cambau E, Bouchon D, Moulin L, Héchard Y. Mycobacterium llatzerense, a waterborne Mycobacterium, that resists phagocytosis by Acanthamoeba castellanii., Sci Rep, 2017, 7, 46270.
19. . Wyplosz B, Mougari F, Al Rawi M, Baillon C ; Marigot-Outtandy D, Le Dû D, Jachym M, Hervé V, Raskine L, Cambau E. Visualizing viable Mycobacterium tuberculosis in sputum to monitor isolation measures. J Infect, 2017, 74, 207-210.
20. . Schön, T ; Miotto, P ; Köser, CU ; Viveiros, M ; Böttger, E ; Cambau, E , Mycobacterium tuberculosis drug- resistance testing : challenges, recent developments and perspectives. Clin Microbiol Infect, 2017, 23, 154-160
21. . Andre, E ; Goeminne, L ; Cabibbe, A ; Beckert, P ; Kabamba Mukadi, B ; Mathys, V & al , Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria., Clin Microbiol Infect, 2017, 23, 167-172
22. . Allerberger, F ; Cambau, E ; Lange, C , Joint efforts urgently needed at times of emerging tuberculosis drug resistance., Clin Microbiol Infect, 2017, 23, 129-130

Publications nationales

1. . Brossier F, Sougakoff W ; French National Reference Center for Mycobacteria(b). Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis. Med Mal Infect. 2017 Jun 17. pii : S0399- 077X(17)30608-X.
2. . CNR des Mycobactéries, J. Robert. Résistance aux antituberculeux en France en 2014-2015. Bulletin Epidemiologique Hebdomadaire 2017 ;7 :127-128.
3. . Bouchet F, Martin B, Aubry A, Veziris N, Lavigne JP, Sotto A. Should single antibiotic therapy be avoided for nontuberculous mycobacteria ? Med Mal Infect. 2017 Dec ;47(8):566-568.
4. . Maitre T, Aubry A, Jarlier V, Robert J, Veziris N ; CNR-MyRMA. Multidrug and extensively drug-resistant tuberculosis. Med Mal Infect. 2017 Feb ;47(1):3-10.

Chapitres d’ouvrage

1. . Aubry, F. Mougari, F. Reibel, E. Cambau. Chapitre Mycobacterium marinum, in “Tuberculosis“, 7th edition, David Schlossberg ed., McGraw-Hill Professional Medical Publishing Division. 2017 & Microbiol Spectr. 2017 Apr ;5(2).
2. . Fraisse P., Veziris N. 2017. Tuberculose pulmonaire et infection tuberculeuse latente. La Pneumologie Fondée sur des Preuves, Editions Margaux Orange.

2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004 / 2003